All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
EN
ČeštinaEnglish

Filters

45 529 (0,123s) •

Result

Sequences for determination of the transcription activity and expression levels of the target gene for 5-azacitidine treatment

Oligonucleotide sequences, designed to measure the relationship between abundance and localization of key molecular factors in samples of tumor cells towards improvement of the diagnosis, prognosis and estimate the potential effectiveness of treatmen...

EB - Genetika a molekulární biologie

  • 2012
    • •
  • Fuzit
    • •
  • Link
Result

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynam...

FD - Onkologie a hematologie

  • 2012
    • •
  • Jx
    • •
  • Link
Result

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was record...

Hematology

  • 2024
    • •
  • Jimp
    • •
  • Link
Result

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

Venetoclax-azacitidine is approved for treatment of patients with newly with venetoclax-azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax-azac...

Hematology

  • 2024
    • •
  • Jimp
    • •
  • Link
Result

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Academic, open label, randomized trial: G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome. GA trial is registered under EudraCT#: 2013-001639-38....

Hematology

  • 2022
    • •
  • Jimp
    • •
  • Link
Result

Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy.

Evaluation of minimal residual disease in patients with De Novo acute myeloid leukemia treated with Azacitidine and Venetoclax combination therapy - conference abstract....

Hematology

  • 2023
    • •
  • O
Result

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT

to Azacitidine Therapy; DRKS00007185) is an investigator-initiated trial that studied EPIC leukaemia (JMML) during therapy with azacitidine. We demonstrate that the pharmacodynamic activity of azacitidine can efficiently b...

Hematology

  • 2025
    • •
  • Jimp
    • •
  • Link
Result

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

prognosis, even after treatment with a hypomethylating agent. Azacitidine added of age or older, or both to azacitidine plus either venetoclax or placebo. All patients received a standard dose of azacitidine (75 mg per squ...

Hematology

  • 2020
    • •
  • Jimp
    • •
  • Link
Result

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

The hypomethylating agents azacitidine (AZA) and decitabine (DEC) have been backbone therapies for older or unfit patients with newly diagnosed acute myeloid leukemia (AML) as single agents and, more recently, in combination with venetoclax....

Hematology

  • 2022
    • •
  • Jimp
    • •
  • Link
Result

Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs

The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs i...

FR - Farmakologie a lékárnická chemie

  • 2016
    • •
  • Jx
    • •
  • Link
  • 1 - 10 out of 45 529